We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New Formulation of BLP25 Liposome Vaccine: Phase II Study Interim Results.
- Abstract
The article announces the interim results of a phase II non-small cell lung cancer (NSCLC) open-label study of BLP25 Liposome Vaccine from Biomira Inc. The reformulated vaccine incorporated manufacturing changes intended to secure the future commercial supply of the vaccine. The company announced that follow-up of patients enrolled in the phase IIB trial had determined a median survival for the vaccinated subset of stage IIIB locoregional patients of 30.6 months compared to 13.3 months observed for the same stage patients who did not receive the vaccine, a difference of 17.3 months.
- Subjects
CLINICAL trials; MEDICAL research; CANCER vaccines; LIPOSOMES; SMALL cell lung cancer; BIOMIRA Inc.; PHARMACEUTICAL industry
- Publication
Oncology (08909091), 2005, Vol 19, Issue 13, p1682
- ISSN
0890-9091
- Publication type
Article